Aspen Pharmacare Holdings Limited (FRA:LDZA)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.11B -2.4% |
| Revenue (ttm) | 2.19B +2.8% |
| Net Income | -102.83M |
| EPS | -0.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 13.80 |
| Dividend | 0.10 (1.59%) |
| Ex-Dividend Date | Oct 1, 2025 |
| Volume | n/a |
| Average Volume | 20 |
| Open | 7.00 |
| Previous Close | 6.95 |
| Day's Range | 7.00 - 7.00 |
| 52-Week Range | 4.50 - 7.50 |
| Beta | n/a |
| RSI | 57.90 |
| Earnings Date | Sep 2, 2026 |
About Aspen Pharmacare Holdings
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counte... [Read more]
News
Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter
Aspen Pharmacare's unbranded version of Novo Nordisk's popular diabetes drug Ozempic could be registered in Canada in the second or third quarter of this year, the South African pharmacueticals g...
South Africa's Aspen Pharmacare to buy Sandoz's China business
Aspen Pharmacare will buy the Chinese business of Swiss group Sandoz , including commercialisation rights and intellectual property for some established products and those in the pipeline, for up to 9...